AVH

Avita Medical Inc.

Pharmaceuticals, Biotechnology & Life Sciences

Avita Medical Inc. is a regenerative medicine company specializing in therapeutic skin restoration. Their flagship product, the RECELL System, is FDA-approved for treating thermal burn wounds and full-thickness skin defects. The company leverages patient-derived skin cells to enhance healing and accelerate recovery, positioning itself as a leader in acute wound care solutions.

regenerative medicine

therapeutic skin restoration

biotechnology

RECELL System

Shorted

short percentage0.18%

reported shorts156.9K

shares on issue86.145M

About

website

avitamedical.com

industry

Pharmaceuticals, Biotechnology & Life Sciences

address

C/- Corporate Creations Network, Inc., S, NEW CASTLE COUNTY, DEL, UNITED STATES OF AMERICA, 19810

Connect

Key Metrics

market cap

$170.76M

eps$-0.51

More Pharmaceuticals, Biotechnology & Life Sciences Stocks

Other shorted stocks in this sector

View all stocks in this industry

Short Position Trends

Track bearish sentiment and short interest over time

Historical Price Data

View stock price movements, volume, and trading patterns

Industry & Focus

regenerative medicine

therapeutic skin restoration

biotechnology

RECELL System

wound care

Company Overview

AI-generated company summary

Company History

Avita Medical Inc. was founded with a focus on developing innovative solutions for skin regeneration. Over the years, the company has evolved to become a leader in therapeutic acute wound care, with its RECELL System receiving FDA approval. Major milestones include expanding its product offerings and securing exclusive rights to distribute PermeaDerm® in the U.S.

Competitive Advantages

Avita Medical's competitive advantages include its FDA-approved RECELL System, which offers a unique approach to skin regeneration by using a patient's own cells. The company's exclusive rights to distribute PermeaDerm® further strengthen its market position in the U.S. Additionally, its focus on accelerating patient recovery times provides a significant clinical advantage.

Risk Factors

•Regulatory changes affecting product approvals
•Competition from other regenerative medicine companies
•Dependence on key product success

Recent Developments

Last 6 months

In the past six months, Avita Medical has focused on expanding its market presence and enhancing its product offerings, particularly with the RECELL System and PermeaDerm® in the U.S.

Key People

Leadership team at Avita Medical Inc.

Cary Vance

Chief Executive Officer

Cary Vance serves as the Interim Chief Executive Officer, bringing extensive leadership experience to guide Avita Medical's strategic direction.

David O'Toole

Chief Financial Officer

David O'Toole is the Chief Financial Officer, responsible for overseeing the company's financial operations and strategies.

Financial Reports

17 reports available

AVITA 10Q Quarterly Report for Q3 2025

Quarterly ReportNov 7, 2025via asx_announcements

Financial Results for Quarter Ending 30 June 2025

Financial ReportAug 8, 2025via asx_announcements

AVITA 10Q Quarterly Report for Q2 2025

Quarterly ReportAug 8, 2025via asx_announcements

AVITA (AVH) Appendix 4D for H1 2025

Half Year ResultsAug 8, 2025via asx_announcements

AVITA Medical to Announce 2nd Quarter 2025 Financial Results

Financial ReportJul 29, 2025via asx_announcements

Financial Results for Quarter Ending 31 March 2025

Financial ReportMay 9, 2025via asx_announcements

AVITA Medical Reports Q1 2025 Financial Results

Financial ReportMay 9, 2025via asx_announcements

Annual Report to Shareholders

Annual ReportFeb 14, 2025via asx_announcements

AVITA Medical Reports Q4 and FY2024 Financial Results

Financial ReportFeb 14, 2025via asx_announcements

AVITA Medical Reports Third Quarter Financial Results

Financial ReportNov 8, 2024via asx_announcements

Showing 10 of 17 reports